Mydecine Innovations Group (NVRS) Stock Price & Analysis

NVRS Stock Chart & Stats

CA$0.05CA$0.00(0.00%)

At close: Oct 30 4:00 PM EDT

Day’s Range: CAD 0.05 - CAD 0.05
52-Week Range: CAD 0.05 - CAD 3.00
Previous Close: CAD 0.05
Volume: 547.18K
Average Volume (3M): 241.24K
Market Cap: CAD 2.63M
Enterprise Value: CAD 73.33M
Total Cash (Recent Filing): N/A
Total Debt (Recent Filing): CAD 4.88M
Price to Earnings (P/E): 0.0
Beta: -11.35
Next Earnings: Nov 17, 2026 (Est.)
EPS Estimate: N/A
Next Dividend Ex-Date: N/A
Dividend Yield: N/A

Mydecine Innovations Group News

Noveris Health Sciences Plans $500,000 Convertible Debenture Financing

Mydecine Innovations Group ( ($TSE:NVRS) ) has provided an update. Noveris Health Sciences Inc. plans a non-brokered private placement of convertible debentures for gross proceeds of up to $500,000, with

2M ago0NF1 NVRS

Noveris Advances Psilocin Analog Patent and Restarts R&D with API

Mydecine Innovations Group ( ($TSE:NVRS) ) has provided an announcement. Noveris Health Sciences has received a Notice of Allowance from the U.S. Patent and Trademark Office for its patent covering

2M ago0NF1 NVRS

Noveris Says No Operational Change Behind Surge in Trading Activity

Mydecine Innovations Group ( ($TSE:NVRS) ) has shared an announcement. Noveris Health Sciences Inc. stated that its management is unaware of any material change in the company’s operations that would

2M ago0NF1 NVRS

Noveris Shares Halted as Company Disavows Promotional Article and FDA Claim

Mydecine Innovations Group ( ($TSE:NVRS) ) has provided an update. Noveris Health Sciences Inc. has had trading in its securities halted by the British Columbia Securities Commission until April 16,

7M ago0NF1 NVRS

Noveris Raises $2.31 Million in LIFE Offering to Advance Mental Health Drug Pipeline

An announcement from Mydecine Innovations Group ( ($TSE:NVRS) ) is now available. Noveris Health Sciences Inc. has closed a non-brokered private placement, issuing 9,625,049 units at $0.24 per unit for

7M ago0NF1 NVRS

Noveris Says No Known Material Change Behind Surge in Trading Activity

An update from Mydecine Innovations Group ( ($TSE:NVRS) ) is now available. Noveris Health Sciences Inc. stated that its management is unaware of any material change in the company’s operations

7M ago0NF1 NVRS

Noveris Health Sciences Boosts Investor Outreach With New Website and Fairfax Partners Mandate

Mydecine Innovations Group ( ($TSE:NVRS) ) just unveiled an announcement. Noveris Health Sciences has launched a new investor-focused website to give shareholders and prospective investors streamlined access to corporate information,

7M ago0NF1 NVRS

Noveris Health Sciences Launches LIFE Private Placement to Fund Mental‑Health Pipeline

An announcement from Mydecine Innovations Group ( ($TSE:NVRS) ) is now available. Noveris Health Sciences plans to raise between $1.5 million and $2.5 million through a non‑brokered private placement under

7M ago0NF1 NVRS

Noveris Health Sciences Names New CEO After Leadership Resignation

An announcement from Mydecine Innovations Group ( ($TSE:NVRS) ) is now available. Noveris Health Sciences Inc., a biotech firm specializing in next-generation psychedelic-based treatments for mental health conditions such as

7M ago0NF1 NVRS

JJK Holdings Buys Major Noveris Convertible Debenture, Paving Way for Potential Control Shift

Mydecine Innovations Group ( ($TSE:NVRS) ) has shared an announcement. Noveris Health Sciences said JJK Holdings has acquired a CAD$7.88 million convertible debenture previously held by Pioneer Garage, in a

8M ago0NF1 NVRS

NVRS FAQ

What was Mydecine Innovations Group’s price range in the past 12 months?

Mydecine Innovations Group lowest stock price was C$0.05 and its highest was C$3.00 in the past 12 months.

What is Mydecine Innovations Group’s market cap?

Mydecine Innovations Group’s market cap is C$2.63M.

When is Mydecine Innovations Group’s upcoming earnings report date?

The company’s upcoming earnings report date is not yet available.

How were Mydecine Innovations Group’s earnings last quarter?

Mydecine Innovations Group released its earnings results on Aug 31, 2026. The company reported C$0 earnings per share for the quarter.

Is Mydecine Innovations Group overvalued?

Not enough analysts have published a price target to calculate whether the price is overvalued.

Does Mydecine Innovations Group pay dividends?

Mydecine Innovations Group does not currently pay dividends.

What is Mydecine Innovations Group’s EPS estimate?

Mydecine Innovations Group’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does Mydecine Innovations Group have?

Mydecine Innovations Group has 58,548,050 shares outstanding.

What happened to Mydecine Innovations Group’s price movement after its last earnings report?

Mydecine Innovations Group reported an EPS of C$0 in its last earnings report. Following the earnings report the stock price went down -11.111%.

Which hedge fund is a major shareholder of Mydecine Innovations Group?

Currently, no hedge funds are holding shares in TSE:NVRS

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description